BiVACOR, a clinical-stage medical device company pioneering a long-term therapy for patients with biventricular heart failure, has secured $18.0 million in funding from investors. This capital infusion will support the continued development and clinical advancement of its innovative Total Artificial Heart (TAH) technology. The company, headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices in Gold Coast, Australia, is focused on addressing the global unmet need for patients with end-stage heart failure.
The BiVACOR TAH represents a significant advancement in artificial heart design. Under the direction of its founder, Daniel Timms, PhD, the device is currently undergoing an FDA-approved first-in-human Early Feasibility Study (EFS). The TAH utilizes magnetic levitation technology, featuring a unique pump design with a single magnetically suspended dual-sided rotor. This design aims to provide a durable, reliable, and biocompatible heart replacement capable of delivering sufficient cardiac output for adults, while minimizing mechanical wear and blood trauma.
The $18.0 million in funding will be strategically deployed to accelerate BiVACOR's clinical development programs, including the ongoing EFS. It will also be used to scale operational capabilities and further refine the BiVACOR TAH as it progresses through its regulatory pathway. This investment underscores confidence in BiVACOR's technology and its potential to offer a life-extending solution for patients awaiting heart transplant.
BiVACOR remains committed to its mission of providing the next generation of solutions for end-stage heart failure. The company anticipates that this funding will enable it to continue its progress in clinical trials, moving closer to making its advanced TAH available to patients globally who currently have limited long-term treatment options.
